Weight-loss jabs will be offered on NHS for people at risk of further heart attacks

• GLP-1 receptor agonists (weight-loss jabs) will now be offered on NHS to over 1 million people in England at high cardiovascular risk, representing a significant expansion beyond current obesity management protocols.
• The primary clinical rationale is secondary prevention—reducing recurrent myocardial infarction and stroke risk in patients with established cardiovascular disease, rather than primary weight management alone.
• GPs should anticipate increased demand for these medications and prepare for patient discussions around eligibility criteria, cardiovascular benefits, and integration into existing heart disease management pathways.

More than a million people in England will start being offered the anti-obesity jab for better heart health and to avoid strokes.

ClinicaliQ summarises and contextualises external updates for clinical awareness, then links to the original publisher for the full article and most current context.